Impaired autophagy in the lower airways and lung parenchyma in stable COPD.


Journal

ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641

Informations de publication

Date de publication:
Nov 2023
Historique:
received: 27 06 2023
accepted: 24 09 2023
medline: 19 12 2023
pubmed: 19 12 2023
entrez: 19 12 2023
Statut: epublish

Résumé

There is increasing evidence of autophagy activation in COPD, but its role is complex and probably regulated through cell type-specific mechanisms. This study aims to investigate the autophagic process at multiple levels within the respiratory system, using different methods to clarify conflicting results reported so far. This cross-sectional study was performed on bronchial biopsies and peripheral lung samples obtained from COPD patients (30 and 12 per sample type, respectively) and healthy controls (25 and 22 per sample type, respectively), divided by smoking history. Subjects were matched for age and smoking history. We analysed some of the most important proteins involved in autophagosome formation, such as LC3 and p62, as well as some molecules essential for lysosome function, such as lysosome-associated membrane protein 1 (LAMP1). Immunohistochemistry was used to assess the autophagic process in both sample types. ELISA and transcriptomic analysis were performed on lung samples. We found increased autophagic stimulus in smoking subjects, regardless of respiratory function. This was revealed by immunohistochemistry through a significant increase in LC3 (p<0.01) and LAMP1 (p<0.01) in small airway bronchiolar epithelium, alveolar septa and alveolar macrophages. Similar results were obtained in bronchial biopsy epithelium by evaluating LC3B (p<0.05), also increased in homogenate lung tissue using ELISA (p<0.05). Patients with COPD, unlike the others, showed an increase in p62 by ELISA (p<0.05). No differences were found in transcriptomics analysis. Different techniques, applied at post-transcriptional level, confirm that cigarette smoke stimulates autophagy at multiple levels inside the respiratory system, and that autophagy failure may characterise COPD.

Sections du résumé

Background UNASSIGNED
There is increasing evidence of autophagy activation in COPD, but its role is complex and probably regulated through cell type-specific mechanisms. This study aims to investigate the autophagic process at multiple levels within the respiratory system, using different methods to clarify conflicting results reported so far.
Methods UNASSIGNED
This cross-sectional study was performed on bronchial biopsies and peripheral lung samples obtained from COPD patients (30 and 12 per sample type, respectively) and healthy controls (25 and 22 per sample type, respectively), divided by smoking history. Subjects were matched for age and smoking history. We analysed some of the most important proteins involved in autophagosome formation, such as LC3 and p62, as well as some molecules essential for lysosome function, such as lysosome-associated membrane protein 1 (LAMP1). Immunohistochemistry was used to assess the autophagic process in both sample types. ELISA and transcriptomic analysis were performed on lung samples.
Results UNASSIGNED
We found increased autophagic stimulus in smoking subjects, regardless of respiratory function. This was revealed by immunohistochemistry through a significant increase in LC3 (p<0.01) and LAMP1 (p<0.01) in small airway bronchiolar epithelium, alveolar septa and alveolar macrophages. Similar results were obtained in bronchial biopsy epithelium by evaluating LC3B (p<0.05), also increased in homogenate lung tissue using ELISA (p<0.05). Patients with COPD, unlike the others, showed an increase in p62 by ELISA (p<0.05). No differences were found in transcriptomics analysis.
Conclusions UNASSIGNED
Different techniques, applied at post-transcriptional level, confirm that cigarette smoke stimulates autophagy at multiple levels inside the respiratory system, and that autophagy failure may characterise COPD.

Identifiants

pubmed: 38111541
doi: 10.1183/23120541.00423-2023
pii: 00423-2023
pmc: PMC10726222
pii:
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Copyright ©The authors 2023.

Déclaration de conflit d'intérêts

Conflict of interest: None declared.

Auteurs

Stefano Levra (S)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Umberto Rosani (U)

Department of Biology, University of Padova, Padua, Italy.

Isabella Gnemmi (I)

Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio, Istituti Clinici Scientifici Maugeri, IRCCS, Veruno (Novara), Italy.

Paola Brun (P)

Department of Molecular Medicine, Histology Unit, University of Padova, Padua, Italy.

Andrea Leonardi (A)

Department of Neuroscience, Ophthalmology Unit, University of Padova, Padua, Italy.

Vitina Carriero (V)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Francesca Bertolini (F)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.

Bruno Balbi (B)

Mondomedico, Novara, Italy.

Mirella Profita (M)

Section of Palermo, Institute of Translational Pharmacology, National Research Council (IFT-CNR), Palermo, Italy.

Fabio Luigi Massimo Ricciardolo (FLM)

Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
Section of Palermo, Institute of Translational Pharmacology, National Research Council (IFT-CNR), Palermo, Italy.
Severe Asthma and Rare Lung Disease Unit, San Luigi Gonzaga University Hospital, Turin, Italy.
These authors contributed equally.

Antonino Di Stefano (A)

Divisione di Pneumologia e Laboratorio di Citoimmunopatologia dell'Apparato Cardio Respiratorio, Istituti Clinici Scientifici Maugeri, IRCCS, Veruno (Novara), Italy.
These authors contributed equally.

Classifications MeSH